

Brainstorm Cell Therapeutics to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston

HACKENSACK, N.J. and PETACH TIKVAH, Israel, April 20, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will present at the Alliance for Regenerative Medicine's (ARM) 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at 09:40 EDT in Boston.

In addition, Dr. Ralph Kern, MD, MHSc, Chief Medical Officer & Chief Operating Officer, will participate in a panel titled "Cell Therapy Beyond Oncology: Where Does The Greatest Potential Lie?".

ARM's 5th Annual Cell & Gene Therapy Investor Day Presentation and Panel Details

Event: **Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day**

Date: April 27, 2017

Time: Presentation (Mr. Lebovits): 09:40 AM EDT
Panel (Dr. Kern): 10:25 AM EDT

Location: The State Room, 60 State Street, Boston, MA 02109

A live video webcast of the presentation will be available at: <http://www.arminvestorday.com/webcast>. The webcast will be posted for further viewing on the event website following the conference.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. Please visit <http://www.arminvestorday.com> for more information.

About ARM's Cell & Gene Therapy Investor Day

Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC

Phone: 646-597-6979
mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-arms-5th-annual-cell--gene-therapy-investor-day-april-27-in-boston-300442562.html>

SOURCE BrainStorm Cell Therapeutics Inc.

Additional assets available online:  [Photos \(1\)](#)

<https://ir.brainstorm-cell.com/2017-04-20-Brainstorm-Cell-Therapeutics-to-Present-at-ARMs-5th-Annual-Cell-Gene-Therapy-Investor-Day-April-27-in-Boston>